Navigation Links
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
Date:5/30/2009

erlotinib for PFS and OS (PFS: hazard ratio [HR] 0.98, 95.22% CI 0.87-1.10; P=0.721; OS: HR 1.01, 95.08% CI 0.89-1.16; P=0.830). Objective response rate and symptom control were also similar for both treatments (ORR: both 12%; symptoms: pain, HR 0.96, P=0.583; dyspnea, HR 1.08, P=0.333; cough, HR 0.94, P=0.403).

The ZEST study was a randomized, double-blind, Phase III study evaluating the efficacy of vandetanib 300mg versus erlotinib 150mg. The study enrolled 1240 patients with locally advanced or metastatic NSCLC after failure of at least one prior anti-cancer therapy.

The most common adverse events observed in the ZEST study were rash, diarrhea and hypertension. Incidence of protocol-defined QTc prolongation was 5.1 percent in the vandetanib arm.

AstraZeneca plans to submit a regulatory submission for the use of vandetanib 100mg in combination with chemotherapy for patients with advanced NSCLC in the first half of 2009.

Evaluation of vandetanib is ongoing, as monotherapy or in combination with other anti-cancer therapies in a range of tumor types, including thyroid cancer.

Results from the ZEPHYR (300mg monotherapy study in EGFR failures in advanced NSCLC, Phase III) and ZETA (300 mg monotherapy in advanced medullary thyroid cancer, Phase III) studies will be available during the second half of 2009.

ZACTIMA(TM) is a trademark of the AstraZeneca group of companies.

About lung cancer

  • Over 1.35 million new cases of lung cancer are diagnosed every year and nearly 1.2 million people die as a result of this devastating disease - more than breast, colon and prostate cancer combined(4).
  • Non-small cell lung cancer accounts for around 85% of all lung cancers(5).
  • If lung cancer is detected at early stages, before it has spread to other organs o
    '/>"/>

SOURCE AstraZeneca Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
2. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
3. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
4. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
5. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
6. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
7. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
8. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
11. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)...  Today, the National Patient Advocate Foundation acknowledges that ... Representatives recently approved a bill that would prohibit insurers ... out-of-pocket fees for newer, more expensive oral anti-cancer drugs ... severe side-effects. However, the bill was amended to include ... to be a barrier to patients with cancer and ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... 15, 2007 - Gemin X Biotechnologies,Inc. announced today ... that its lead compound, obatoclax (GX15-070), induced,cell death ... lines and,primary cells from 11 MCL patients. Obatoclax ... all relevant members of,the Bcl-2 protein family, a ...
... Showed Bioequivalence , LONDON, UK and ATLANTA, US, ... Sciele Pharma. Inc. (NASDAQ:SCRX) today,announce the successful completion ... of Sular, a calcium ,channel blocking agent for ... showed that the new Sular formulation is,bioequivalent to ...
Cached Medicine Technology:Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 2SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 3
(Date:5/19/2013)... 19, 2013 Exciting new Skin Brushes ... reintroducing a great practice known through the ages but ... as dry body brushing, has so many benefits for ... Sublime Beauty®. "We love that circulation and lymphatic systems ... organ, the skin, is supported through Skin Brushing." , ...
(Date:5/19/2013)... Buenos Aires, Argentina: Yoga classes ( clases de Yoga ... by the Sivananda Yoga Vedanta Center. The center ... Norte). Classes are 90 minutes and are offered all ... a calm environment, allowing visitors to enjoy the benefits ... among others. , The Yoga classes follow the following ...
(Date:5/19/2013)... May 19, 2013 Minor fender benders ... road that require parties to the accident to respond ... Disease Control and Prevention (CDC) data from 2010, accidents, ... death (i). In fact, in 2005, automobile ... Additionally, more than 2.3 million drivers and passengers ...
(Date:5/18/2013)... Cambridge House of Maryville , a ... East area, is hosting a Memorial Day Weekend Barbecue from ... The community, which is located at 6960 State Rte. 162 ... those on Medicaid, who need some help to maintain their ... off by homemade ice cream for dessert,” says Tracy Skaer-Henry, ...
(Date:5/18/2013)... 2013 The American Society for Gastrointestinal Endoscopy (ASGE) ... during the ninth annual ASGE Crystal Awards on Sunday, ... Foundation, this year,s event will begin at ... , Held in conjunction with Digestive Disease Week ... leadership, research and scientific pursuit. The event will recognize ...
Breaking Medicine News(10 mins):Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2Health News:Metro East Affordable Assisted Living Community to Host Memorial Day Weekend Barbecue 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7
... ... Aging Month, an annual observance designed to raise awareness on the positive aspects of ... of the nation,s largest not-for-profit aging services organizations, offer the following simple and effective ... ...
... , Proposed law would regulate teens, right to ... the military , , WASHINGTON, Aug. 18 ... Suffolk teens under the age of 18 from using a sun-bed. ... the following statement regarding the bill: , , It ...
... , , EMERYVILLE, Calif., ... company, announced today that it has closed a $40 million Series ... Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also ... company announced the election of George M. Rehm, Managing Partner of ...
... New data show nanotechnology-related activities in every ... Aug. 18 Every state can now lay claim to the ... by the Project on Emerging Nanotechnologies (PEN) highlights more than 1,200 ... states and in the District of Columbia that are involved in ...
... cardiovascular complications , TUESDAY, Aug. 18 (HealthDay News) ... snoring, interrupted breathing and sleep disruption -- nearly double ... middle-aged and elderly men, according to major new research. ... an increased death risk, as much as 17 percent, ...
... , SCHAUMBURG, Ill., Aug. 18 The ... Motor o la, Inc. (NYSE: MOT ... Vulnerability Assessment solution , a patented wireless security technology aimed at proactively ... new method to secure wi r eless networks ...
Cached Medicine News:Health News:7 Easy Tips for Healthy Aging 2Health News:Indoor Tanning Association Opposes Suffolk Bill Banning Teens From Sun-Beds 2Health News:Adamas Pharmaceuticals Raises $40 Million in Series D Financing 2Health News:Adamas Pharmaceuticals Raises $40 Million in Series D Financing 3Health News:Putting Nanotechnology on the Map 2Health News:Putting Nanotechnology on the Map 3Health News:Sleep Apnea Raises Risk of Death, Especially for Men: Report 2Health News:Sleep Apnea Raises Risk of Death, Especially for Men: Report 3Health News:Sleep Apnea Raises Risk of Death, Especially for Men: Report 4Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 2Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 3Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 4Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 5
... Wavefront analysis with the WASCA Analyzer ... diagnosis. Unlike existing diagnostic techniques, the WASCA ... eye from thecornea to the retina. ... Analyzer also supplies higher order aberrations which ...
... is a flexible, total solution. , ,Kojair Tech ... since 1983. A major part of our production ... from all the different areas of clean-air needs ... Tech Oy is a comprehensive supplier. We are ...
The Universal Knee Positioner(s)™ reduces surgeon fatigue while assisting in the stabilization of a patient's leg during surgury....
The De mayo Hip Positioner is simple, adjustable, has lateral decubitus positioning, and can be set up with six simple steps....
Medicine Products: